AptarGroup, a company based outside of Chicago, Illinois, has announced that the FDA recently approved a medication (NAYZILAM (midazolam)) for treatment of acute repetitive epileptic seizures and that the company’s Unidose Liquid System was chosen as the delivery mechanism for this rescue drug.
The Unidose Liquid System doesn’t require priming and can be used with one hand, from any direction, to delivery the medicine directly into the nose. To help train patients and caretakers on how to administer the drug, Aptar had its new subsidiary, Noble International, design a trainer device that mimics the real deal. In reality, the system can be easily used by a bystander with little training, but it certainly helps to be familiar with the product ahead of an emergency.
“The launch of our Unidose System on the first and only U.S. FDA approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments,” stated Gael Touya, President, Aptar Pharma, in a press release. “When we combine our nasal systems’ capabilities with Noble’s training devices for onboarding, we bring added value to our customers and further convenience for patients and consumers worldwide.”
Product page: Unidose System